Kyverna Therapeutics Has Been Granted FDA Fast Track Designation for KYV-101 in the Treatment of Individuals With Refractory Myasthenia Gravis
Thursday, December 14, 2023
Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, has received fast track designation from the U.S. Food and Drug Administration (FDA) for its autologous CD19 chimeric antigen receptor (CAR) T-cell product, KYV-101. This designation is specifically for the treatment of myasthenia gravis (MG), a severe neurological autoimmune disease.
The fast track designation is a program by the FDA intended to expedite the development and review of new drugs that address unmet medical needs for serious or life-threatening conditions.
Peter Maag, CEO of Kyverna, expressed the company's satisfaction with receiving this important designation for KYV-101 in the KYSA-6 trial. He emphasized Kyverna's dedication to improving the lives of patients with challenging neurological autoimmune diseases. This marks the second time KYV-101 has received such recognition, following its earlier designation for lupus nephritis.
CAR T-cell therapy involves modifying a patient's T cells to target and eliminate B cells in the body. KYV-101, Kyverna's CD19 CAR T-cell therapy, specifically targets CD19, a protein expressed on the surface of B cells, implicated in various autoimmune diseases. Kyverna plans to explore additional indications for KYV-101, aiming to develop a robust pipeline of immunotherapies addressing unmet medical needs in autoimmune diseases.
Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness throughout the body. Symptoms may include partial paralysis of eye movements, difficulties in chewing and swallowing, respiratory problems, speech issues, and weakness in skeletal muscles. KYV-101 aims to address MG by targeting the immunological attack on critical signaling proteins associated with the disease.
KYV-101, an autologous CD19 CAR T-cell product candidate, was initially designed by the National Institutes of Health (NIH) to enhance tolerability. Results from a 20-patient Phase 1 trial in oncology, published by the NIH in Nature Medicine, demonstrated promising outcomes. Kyverna is currently conducting trials of KYV-101 in lupus nephritis, with additional trials in systemic sclerosis, myasthenia gravis, and multiple sclerosis in preparation. The unique properties of KYV-101 are believed to be crucial for the potential success of CAR T cells as therapies for autoimmune diseases.
Source: prnewswire.com
